HOME >> MEDICINE >> NEWS
Twice daily imatinib could improve outcome for people with specific form of gastro-intestinal cancer

This release is also available in German.

Results of a randomised trial in this week's issue of THE LANCET suggest that a single daily 400 mg dose of imatinib--known to be a first-choice treatment for gastro-intestinal stromal tumours (GIST)--is sufficient to induce a therapeutic response; a doubling of a daily dose can slightly improve progression-free survival for patients.

Imatinib is approved worldwide for use in GIST, tumours which do not respond to conventional chemotherapy, which have a prevalence of around 20 per 100,000 population. Jaap Verweij (Erasmus University Medical Center, Netherlands) and colleagues from the European Organisation for Research and Treatment of Cancer (EORTC), the Italian Sarcoma Group (IRG), and the australasian Gastrointestinal Trials Group (AGITG) studied 946 patients with metastatic GIST who were randomly allocated either imatinib 400 mg once or twice a day.

50% of patients receiving two doses of imatinib a day, compared with 56% of patients given a single dose, were alive and free of disease progression at around 2 years follow-up. There was no difference in the proportion of patients (99%) who reported treatment side-effects; the optimum time for therapeutic effect after the start of treatment did not differ between the two groups (around 4 months).

Dr Verweij comments: "If the aim of treatment is response induction, a daily dose of 400 mg given for 46 months seems to be sufficient. However, in patients with widespread metastatic disease, the prolonged progression-free survival achieved with 400 mg twice daily might lead one to favour this regimen. Whether a similar outcome could be achieved with fewer side-effects by making use of the reduction in drug clearance over time--eg, with a starting dose of 400 mg daily followed by stepwise dose escalation to 400 mg twice a day--is still a matter for further clini
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
23-Sep-2004


Page: 1 2

Related medicine news :

1. Study: Among Heart Failure Patients, Women Survive Twice As Long As Men
2. Bullying among sixth graders a daily occurrence, UCLA study finds
3. Current daily smoking may be associated with increased risk for suicidal thoughts and attempts
4. African children with HIV would benefit from daily doses of cheap antibiotic
5. Weekend use matches daily drops for lazy eye
6. New ways identified to treat lazy eye in children: Beyond eye patches and daily drops
7. Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment
8. Study finds once-daily Valcyte prevents serious viral infection after kidney transplant
9. Max daily OTC dose of acetaminophen shows efficacy comparable to Rx doses of naproxen for OA pain
10. New study finds even a small amount of psoriasis can negatively impact daily life
11. OHSU study shows four daily servings of fruits & vegetables reduce breast cancer risk by half

Post Your Comments:
(Date:11/24/2014)... 2014 The Mesothelioma Applied Research ... International Symposium on Malignant Mesothelioma from March 2nd through ... sessions will take place on the campus of the ... a community dinner and an awards ceremony, will be ... cover a range of topics about pleural and peritoneal ...
(Date:11/24/2014)... UK (PRWEB) November 24, 2014 ... Massaggi , London's pre-eminent pain-relief service and massage ... Emmett Sports Massage (ESM). This newest sports ... , The key difference between traditional sports massage ... to access the body's very own "reset button,” ...
(Date:11/24/2014)... SWAccessControl.com has recently released a new collection ... the company is a leading online supplier in the international ... available at discounted prices, up to 30% off. , “We ... This time, all of our items are offered at low ... so I have confidence in our fresh assortment. You will ...
(Date:11/24/2014)... Philadelphia, PA (PRWEB) November 24, 2014 ... care coordination and disease management services to health ... to implement Essette’s Medical Management software suite. ... SaaS platform in a program to reduce patients' ... includes Population Health Management, Care Management, Utilization Management, ...
(Date:11/23/2014)... 24, 2014 The clinical trial ... provides data on the Aspergillosis clinical trial scenario. ... to the clinical trials on Aspergillosis. It includes ... recruitment status as per the site of trial ... preliminary coverage of disease clinical trials by their ...
Breaking Medicine News(10 mins):Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 2Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 3Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 3Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4
(Date:11/23/2014)... , Nov. 23, 2014  Aurobindo Pharma ... of Gabapentin Capsules, USP 300 mg 100-count bottles to ... to contain some empty capsules. Empty capsules ... adverse health consequences that could range from no effect, ... or status epilepticus (long period seizures) that could be ...
(Date:11/22/2014)... -- New data demonstrates that flibanserin, a novel, non-hormonal medicine ... sexual dysfunction, Hypoactive Sexual Desire Disorder (HSDD), does not ... women when taken at bedtime. The data was presented ... America,s (SMSNA) 20th Annual Fall Scientific Meeting ... SMSNA accepted this study as a late breaking abstract ...
(Date:11/22/2014)... , 21 de noviembre de 2014  BioClinica®, ... clínicos externalizados y tecnologías eClinical, ha indicado un ... ,seguimiento inteligente, para el seguimiento basado en el ... amplía el concepto del seguimiento basado en el ... las visitas de seguimiento o cambio de los ...
Breaking Medicine Technology:Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
Cached News: